A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Clinical trial NCT07058077 · RECRUITING
Trial details
- NCT number
- NCT07058077
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-21
- Primary completion
- 2033-12-04
- Enrollment
- 153
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.